40
Participants
Start Date
April 10, 2023
Primary Completion Date
April 15, 2025
Study Completion Date
April 15, 2025
Bumetanide
Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
Placebo
A placebo has no active properties and is taken orally.
RECRUITING
Stanford University, Stanford
Stanford University
OTHER